Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 608415, 10 pages
http://dx.doi.org/10.1155/2013/608415
Research Article

Genetic Markers Associated to Dyslipidemia in HIV-Infected Individuals on HAART

1Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil
2Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite 245, Sala 309, 90050-170 Porto Alegre, RS, Brazil
3Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Instituto de Avaliação de Tecnologias em Saúde, 90035-903 Porto Alegre, RS, Brazil
4Hospital Universitário Dr. Miguel Riet Correa Jr., 96200-000 Rio Grande, RS, Brazil
5Serviço de Assistência Especializada em HIV/AIDS, Universidade Federal de Pelotas, 96030-001 Pelotas, RS, Brazil
6Serviço de Medicina Interna, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil

Received 31 July 2013; Accepted 28 August 2013

Academic Editors: S. C. Fuchs, M. B. Moreira, and B. Oyeledun

Copyright © 2013 Rosmeri K. Lazzaretti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. O. Taiwo, X. Li, F. Palella et al., “Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART,” HIV Medicine, vol. 10, no. 10, pp. 657–660, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. P. Marins, L. F. Jamal, S. Y. Chen et al., “Dramatic improvement in survival among adult Brazilian AIDS patients,” AIDS, vol. 17, no. 11, pp. 1675–1682, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. P. Dubé, J. H. Stein, J. A. Aberg et al., “Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group,” Clinical Infectious Diseases, vol. 37, no. 5, pp. 613–627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Fox, M. Boffito, and A. Winston, “The clinical implications of antiretroviral pharmacogenomics,” Pharmacogenomics, vol. 7, no. 4, pp. 587–596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M.-H. Chang, A. Yesupriya, R. M. Ned, P. W. Mueller, and N. F. Dowling, “Genetic variants associated with fasting blood lipids in the U.S. population: third National Health and Nutrition Examination Survey,” BMC Medical Genetics, vol. 11, no. 1, article 62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. M. de Andrade, S. W. Maluf, J. B. Schuch et al., “The influence of the S19W SNP of the APOA5 gene on triglyceride levels in southern Brazil: interactions with the APOE gene, sex and menopause status,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 8, pp. 584–590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Fiegenbaum, F. R. Silveira, C. R. van der Sand et al., “Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes,” Pharmacogenomics Journal, vol. 5, no. 6, pp. 359–364, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Fiegenbaum, F. M. de Andrade, and M. H. Hutz, “Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes,” Clinica Chimica Acta, vol. 380, no. 1-2, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. L. S. Rios, A. F. Vargas, M. R. Torres, A. J. Zago, S. M. Callegari-Jacques, and M. H. Hutz, “Interaction between SREBP-1a and APOB polymorphisms influences total and low-density lipoprotein cholesterol levels in patients with coronary artery disease,” Clinical Genetics, vol. 63, no. 5, pp. 380–385, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Arnedo, P. Taffé, R. Sahli et al., “Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy,” Pharmacogenetics and Genomics, vol. 17, no. 9, pp. 755–764, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Rotger, C. Bayard, P. Taffé et al., “Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study,” Circulation, vol. 2, no. 6, pp. 621–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Kathiresan, C. J. Willer, G. M. Peloso et al., “Common variants at 30 loci contribute to polygenic dyslipidemia,” Nature Genetics, vol. 41, no. 1, pp. 56–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Sandhu, D. M. Waterworth, S. L. Debenham et al., “LDL-cholesterol concentrations: a genome-wide association study,” The Lancet, vol. 371, no. 9611, pp. 483–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Wallace, S. J. Newhouse, P. Braund et al., “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia,” American Journal of Human Genetics, vol. 82, no. 1, pp. 139–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Schneider, S. Whitmore, K. M. Glynn, K. Dominguez, A. Mitsch, and M. T. McKenna, “Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008,” Morbidity and Mortality Weekly Report, vol. 57, no. 10, pp. 1–12, 2008. View at Google Scholar · View at Scopus
  16. V. M. Zembrzuski, S. M. Callegari-Jacques, and M. H. Hutz, “Application of an African ancestry index as a genomic control approach in a Brazilian population,” Annals of Human Genetics, vol. 70, no. 6, pp. 822–828, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. N. P. C. Santos, E. M. Ribeiro-Rodrigues, Â. K. C. Ribeiro-dos-Santos et al., “Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel,” Human Mutation, vol. 31, no. 2, pp. 184–190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar · View at Scopus
  19. D. K. Lahiri and J. L. Nurnberger Jr., “A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies,” Nucleic Acids Research, vol. 19, no. 19, p. 5444, 1991. View at Google Scholar · View at Scopus
  20. P. E. Pajukanta, L. M. Valsta, A. Aro, P. Pietinen, T. Heliö, and M. J. Tikkanen, “The effects of the apolipoprotein B signal peptide (ins/del) and XbaI polymorphisms on plasma lipid responses to dietary change,” Atherosclerosis, vol. 122, no. 1, pp. 1–10, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-P. Pan, A.-N. Chiang, J. J. Tai, S.-P. Wang, and M.-S. Chang, “Restriction fragment length polymorphisms of apolipoprotein B gene in Chinese population with coronary heart disease,” Clinical Chemistry, vol. 41, no. 3, pp. 424–429, 1995. View at Google Scholar · View at Scopus
  22. D. A. Tregouet and V. Garelle, “A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies,” Bioinformatics, vol. 23, no. 8, pp. 1038–1039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. E. R. Feeney and P. W. G. Mallon, “HIV and HAART-associated dyslipidemia,” The Open Cardiovascular Medicine Journal, vol. 5, pp. 49–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. P. E. Tarr, P. Taffe, G. Bleiber et al., “Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy—associated lipid disorders,” Journal of Infectious Diseases, vol. 191, pp. 1419–1426, 2005. View at Google Scholar
  25. J. M. Ordovas, J. Lopez-Miranda, F. Perez-Jimenez et al., “Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy,” Atherosclerosis, vol. 113, no. 2, pp. 157–166, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Pedro-Botet, E. J. Schaefer, R. G. Bakker-Arkema et al., “Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner,” Atherosclerosis, vol. 158, no. 1, pp. 183–193, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. R. W. Mahley and S. C. Rall Jr., “Apolipoprotein E: far more than a lipid transport protein,” Annual Review of Genomics and Human Genetics, vol. 1, no. 2000, pp. 507–537, 2000. View at Google Scholar · View at Scopus
  28. A. M. Bennet, E. di Angelantonio, Z. Ye et al., “Association of apolipoprotein e genotypes with lipid levels and coronary risk,” Journal of the American Medical Association, vol. 298, no. 11, pp. 1300–1311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Fauvel, E. Bonnet, J.-B. Ruidavets et al., “An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients,” AIDS, vol. 15, no. 18, pp. 2397–2406, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Marzocchetti, J. Schwarz, S. di Giambenedetto et al., “The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 27, no. 12, pp. 1299–1309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Seda and L. Sedova, “New Apolipoprotein A-V: comparative genomics meets metabolism,” Physiological Research, vol. 52, pp. 141–146, 2003. View at Google Scholar
  32. E. S. Tai and J. M. Ordovas, “Clinical significance of apolipoprotein A5,” Current Opinion in Lipidology, vol. 19, no. 4, pp. 349–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C.-Q. Lai, E.-S. Tai, C. E. Tan et al., “The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore,” Journal of Lipid Research, vol. 44, no. 12, pp. 2365–2373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Guardiola, R. Ferré, J. Salazar et al., “Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T→C gene variation,” Clinical Chemistry, vol. 52, no. 10, pp. 1914–1919, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Kay, W. März, M. M. Hoffmann et al., “Coronary artery disease and dyslipidemia within Europe: genetic variants in lipid transport gene loci in German subjects with premature coronary artery disease,” Atherosclerosis Supplements, vol. 3, no. 1, pp. 27–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. P. R. Turner, P. J. Talmud, S. Visvikis, C. Ehnholm, and L. Tiret, “DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: european Atherosclerosis Research Study,” Atherosclerosis, vol. 116, no. 2, pp. 221–234, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Benn, B. G. Nordestgaard, J. S. Jensen, P. Grande, H. Sillesen, and A. Tybjærg-Hansen, “Polymorphism in APOB associated with increased low-density lipoprotein levels in both genders in the general population,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 10, pp. 5797–5803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. C.-F. Xu, M. J. Tikkanen, J. K. Huttunen et al., “Apolipoprotein B signal peptide insertion/deletion polymorphism is associated with Ag epitopes and involved in the determination of serum triglyceride levels,” Journal of Lipid Research, vol. 31, no. 7, pp. 1255–1261, 1990. View at Google Scholar · View at Scopus
  39. P. Ye, B. Chen, and S. Wang, “Association of polymorphisms of the apolipoprotein B gene with coronary heart disease in Han Chinese,” Atherosclerosis, vol. 117, no. 1, pp. 43–50, 1995. View at Publisher · View at Google Scholar · View at Scopus